Matches in Wikidata for { <http://www.wikidata.org/entity/Q92083800> ?p ?o ?g. }
Showing items 1 to 42 of
42
with 100 items per page.
- Q92083800 description "article scientifique publié en 2020" @default.
- Q92083800 description "artículu científicu espublizáu n'abril de 2020" @default.
- Q92083800 description "scientific article published on 01 April 2020" @default.
- Q92083800 description "wetenschappelijk artikel" @default.
- Q92083800 description "наукова стаття, опублікована 1 квітня 2020" @default.
- Q92083800 name "In patients with no indication for anticoagulation after TAVR, rivaroxaban increased adverse events vs antiplatelets" @default.
- Q92083800 name "In patients with no indication for anticoagulation after TAVR, rivaroxaban increased adverse events vs antiplatelets" @default.
- Q92083800 type Item @default.
- Q92083800 label "In patients with no indication for anticoagulation after TAVR, rivaroxaban increased adverse events vs antiplatelets" @default.
- Q92083800 label "In patients with no indication for anticoagulation after TAVR, rivaroxaban increased adverse events vs antiplatelets" @default.
- Q92083800 prefLabel "In patients with no indication for anticoagulation after TAVR, rivaroxaban increased adverse events vs antiplatelets" @default.
- Q92083800 prefLabel "In patients with no indication for anticoagulation after TAVR, rivaroxaban increased adverse events vs antiplatelets" @default.
- Q92083800 P1433 Q92083800-3FE96DE3-3A48-4AF1-BC02-2A304334B700 @default.
- Q92083800 P1476 Q92083800-32C3F54E-2BCC-4058-8068-6BB055B42B34 @default.
- Q92083800 P2093 Q92083800-D67A3BD7-52B1-4350-93A1-0A37942D3255 @default.
- Q92083800 P2093 Q92083800-ED818D54-48D1-4135-A4F5-44007B715415 @default.
- Q92083800 P304 Q92083800-DE44BACB-F8C5-42F4-A83A-666C32CE348D @default.
- Q92083800 P31 Q92083800-7353A150-7B24-45E4-9C6A-D324B4F0239A @default.
- Q92083800 P356 Q92083800-277D77E9-A433-4840-A0F0-49D92165F640 @default.
- Q92083800 P433 Q92083800-6478FB0C-A059-43F7-BE47-E2A5295B4CF4 @default.
- Q92083800 P478 Q92083800-8F759B52-8820-41A9-BA54-93FDFD5FDB61 @default.
- Q92083800 P50 Q92083800-401AF8DA-04D6-4062-BAC3-670684041325 @default.
- Q92083800 P577 Q92083800-4F5C00F0-9BB3-4849-A39F-EB1900E1192C @default.
- Q92083800 P698 Q92083800-BFE5D71B-0C2B-4E85-BFF5-EBEC29B56F1B @default.
- Q92083800 P921 Q92083800-78B04755-AA55-4173-B96E-1819B5CA1AB6 @default.
- Q92083800 P921 Q92083800-9800DE90-E458-4FBD-A751-9C93D76655E8 @default.
- Q92083800 P356 ACPJ202004210-040 @default.
- Q92083800 P698 32311724 @default.
- Q92083800 P1433 Q564416 @default.
- Q92083800 P1476 "In patients with no indication for anticoagulation after TAVR, rivaroxaban increased adverse events vs antiplatelets" @default.
- Q92083800 P2093 "Mark Field" @default.
- Q92083800 P2093 "Wern Yew Ding" @default.
- Q92083800 P304 "JC40" @default.
- Q92083800 P31 Q13442814 @default.
- Q92083800 P356 "10.7326/ACPJ202004210-040" @default.
- Q92083800 P433 "8" @default.
- Q92083800 P478 "172" @default.
- Q92083800 P50 Q60393087 @default.
- Q92083800 P577 "2020-04-01T00:00:00Z" @default.
- Q92083800 P698 "32311724" @default.
- Q92083800 P921 Q63279445 @default.
- Q92083800 P921 Q7167196 @default.